{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:10:12Z","timestamp":1791274212674,"version":"4.1.0"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:p>Primary IgA nephropathy (IgAN) is the most common form of primary glomerulopathy. A slowly progressive disease presenting in the young to middle-aged, most patients with reduced eGFR or proteinuria will progress to end-stage kidney disease (ESKD) in their lifetimes. The pathogenesis involves increased production of galactose-deficient IgA1 (Gd-IgA1) that forms immune complexes that deposit in the glomerulus, eliciting mesangial cell proliferation, inflammation, and complement activation. The backbone of therapy is supportive, including lifestyle modifications, strict blood pressure control, and renin-angiotensin system inhibition targeting proteinuria &amp;lt; 300 mg\/day. Sodium-glucose transporter 2 inhibitors are indicated for persisting proteinuria or declining eGFR. Sparsentan is indicated for persisting proteinuria. Immunosuppression should be considered for all patients at risk for progression (persisting proteinuria and\/or declining eGFR). To reduce Gd-IgA1 production, targeted-release budesonide is approved. Agents targeting B cell survival factors APRIL or BAFF\/APRIL have significantly reduced Gd-IgA1 production and proteinuria in phase 2 trials but await phase 3 data for approval. To reduce inflammation, high-dose steroids are ineffective and toxic in Caucasian patients, although lower-dose regimens may be effective in Chinese patients. Complement inhibition is being actively studied. The factor B inhibitor iptacopan has conditional approval. The terminal pathway inhibitors cemdisiran and ravulizumab show promise in phase 2 studies. Our current approach for those requiring immunosuppression involves combining the reduction of Gd-IgA1 (nefecon) with suppressing the effects of inflammation (iptacopan). The optimal duration of such therapy is uncertain. Clearly, there is more to be learned with many trials underway.<\/jats:p>","DOI":"10.3389\/fneph.2025.1545329","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:28:34Z","timestamp":1738646914000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["The road ahead: emerging therapies for primary IgA nephropathy"],"prefix":"10.3389","volume":"5","author":[{"given":"Edward J.","family":"Filippone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Farber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1436923","article-title":"Contemporary review of IgA nephropathy","volume":"15","author":"Filippone","year":"2024","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2018.05.015","article-title":"Genetic determinants of IgA nephropathy: Eastern perspective","volume":"38","author":"Li","year":"2018","journal-title":"Semin Nephrol"},{"key":"B6","article-title":"Is IgA class switching epigenetically wired?: Untangling the evidence","volume":"35","author":"Quinn","year":"9900","journal-title":"J Am Soc Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adl6149","article-title":"The gut microbiota posttranslationally modifies IgA1 in autoimmune glomerulonephritis","volume":"16","author":"Gleeson","year":"2024","journal-title":"Sci Trans Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate end point for kidney disease progression in clinical trials: A meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","article-title":"Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: Secondary analyses of the EMPA-KIDNEY trial","volume":"12","author":"Judge","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.07.023","article-title":"Targeting the endothelin A receptor in IgA nephropathy","volume":"8","author":"Kohan","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): A double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): A multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00569-X","article-title":"Sparsentan in patients with IgA nephropathy: A prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial","volume":"401","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.ekir.2023.02.1088","article-title":"Wcn23-1126 atrasentan for the treatment of iga nephropathy: Interim results of the affinity study","volume":"8","author":"Kim","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","author":"Heerspink","year":"2024","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1681\/ASN.0000000538","article-title":"The selective endothelin receptor antagonist SC0062 in IgA nephropathy: A randomized double-blind placebo-controlled clinical trial","volume":"10","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"FR-PO851","DOI":"10.1681\/ASN.2024f91q2ank","article-title":"Concomitant sparsentan (SPAR) and SGLT2 inhibitors in patients with IgA nephropathy in the PROTECT open-label extension (OLE): FR-PO851","volume":"35","author":"Kooienga","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"FR-PO852","DOI":"10.1681\/ASN.2024tg9t6qtt","article-title":"First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors: FR-PO852","volume":"35","author":"Schanz","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1997.361","article-title":"Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG","volume":"52","author":"Tomana","year":"1997","journal-title":"Kidney Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00871-y","article-title":"The mucosal immune system and IgA nephropathy","volume":"43","author":"Gesualdo","year":"2021","journal-title":"Semin Immunopathology"},{"key":"B27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1136\/jcp.49.1.38","article-title":"Increased dimeric IgA producing B cells in the bone marrow in IgA nephropathy determined by in situ hybridisation for J chain mRNA","volume":"49","author":"Harper","year":"1996","journal-title":"J Clin Pathol"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for reduction of proteinuria in IgA nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2023.1346769","article-title":"The role of BAFF and APRIL in IgA nephropathy: Pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2024","journal-title":"Front Nephrol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.08.012","article-title":"Targeting APRIL in the treatment of glomerular diseases","volume":"106","author":"Cheung","year":"2024","journal-title":"Kidney Int"},{"key":"B32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cellimm.2006.08.002","article-title":"BAFF induces a hyper-IgA syndrome in the intestinal lamina propria concomitant with IgA deposition in the kidney independent of LIGHT","volume":"241","author":"McCarthy","year":"2006","journal-title":"Cell Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.01.031","article-title":"A proliferation inducing ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy","volume":"96","author":"Myette","year":"2019","journal-title":"Kidney Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.5301\/jn.5000218","article-title":"Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features","volume":"26","author":"Xin","year":"2013","journal-title":"J Nephrol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003099","article-title":"Increased APRIL expression induces IgA1 aberrant glycosylation in IgA nephropathy","volume":"95","author":"Zhai","year":"2016","journal-title":"Med (Baltimore)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","article-title":"A phase 2 trial of sibeprenlimab in patients with IgA nephropathy","volume":"390","author":"Mathur","year":"2024","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"gfab117.004","DOI":"10.1093\/ndt\/gfab117.004","article-title":"FC 040 interim results of phase 1 and 2 trials to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of BION-1301 in patients with IgA nephropathy","volume":"36","author":"Barratt","year":"2021","journal-title":"Nephrol Dialysis Transplant"},{"key":"B39","doi-asserted-by":"crossref","first-page":"FR-PO856","DOI":"10.1681\/ASN.2024hy3jwqbb","article-title":"A phase 1\/2 trial of zigakibart in IgA nephropathy: FR-PO856","volume":"35","author":"Barratt","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.05.017","article-title":"Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.03.012","article-title":"A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy","volume":"105","author":"Lafayette","year":"2024","journal-title":"Kidney Int"},{"key":"B42","article-title":"Long-term results from an open-label extension study of atacicept for the treatment of IgA nephropathy","author":"Barratt","year":"9900","journal-title":"J Am Soc Nephrol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","article-title":"Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria","volume":"8","author":"Lv","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B44","first-page":"FR-PO854","article-title":"Results from longer follow-up with povetacicept, an enhanced dual BAFF\/APRIL antagonist, in IgA nephropathy (RUBY-3 study): FR-PO854","volume":"35","author":"Madan","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"gfad063a_3347","DOI":"10.1093\/ndt\/gfad063a_3347","article-title":"3347 COVID vaccine responses during sibeprenlimab treatment of IgA nephropathy (IgAN): An interim analysis","volume":"38","author":"Mccafferty","year":"2023","journal-title":"Nephrol Dialysis Transplant"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.11.003","article-title":"Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: Insights from the NEFIGAN trial","volume":"105","author":"Wimbury","year":"2024","journal-title":"Kidney Int"},{"key":"B48","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00460.x","article-title":"Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy","volume":"68","author":"Tang","year":"2005","journal-title":"Kidney Int"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1159\/000168483","article-title":"Mycophenolate mofetil treatment for IgA nephropathy: A meta-analysis","volume":"29","author":"Xu","year":"2009","journal-title":"Am J Nephrol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-15-193","article-title":"Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: A systematic review","volume":"15","author":"Chen","year":"2014","journal-title":"BMC Nephrol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s10157-021-02028-5","article-title":"Efficacy and safety of mycophenolate mofetil in the treatment for IgA nephropathy: A meta-analysis of randomized controlled trials","volume":"25","author":"Peng","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.54054","article-title":"Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: A randomized clinical trial","volume":"6","author":"Hou","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2174\/0113816128304327240620093048","article-title":"Treatment of patients with IgA nephropathy: Evaluation of the safety and efficacy of mycophenolate mofetil","volume":"30","author":"Chen","year":"2024","journal-title":"Curr Pharm Des"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.08.022","article-title":"TLR9 activation induces aberrant IgA glycosylation via APRIL-and IL-6\u2013mediated pathways in IgA nephropathy","volume":"97","author":"Makita","year":"2020","journal-title":"Kidney Int"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.08.013","article-title":"The nucleotide-sensing toll-like receptor 9\/toll-like receptor 7 system is a potential therapeutic target for IgA nephropathy","volume":"104","author":"Lee","year":"2023","journal-title":"Kidney Int"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2021.2000875","article-title":"Hydroxychloroquine in IgA nephropathy: A systematic review","volume":"43","author":"Stefan","year":"2021","journal-title":"Ren Fail"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-023-03238-7","article-title":"Comparison between hydroxychloroquine and systemic corticosteroids in IgA nephropathy: A two-year follow-up study","volume":"24","author":"Si","year":"2023","journal-title":"BMC Nephrol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: A randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011111112","article-title":"Corticosteroid therapy in IgA nephropathy","volume":"23","author":"Lv","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.04.046","article-title":"After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy","volume":"98","author":"Rauen","year":"2020","journal-title":"Kidney Int"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.09.027","article-title":"Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy","volume":"105","author":"Zhang","year":"2024","journal-title":"Kidney Int"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/10.7.1166","article-title":"The pathogenetic significance of C5b-9 in IgA nephropathy","volume":"10","author":"Alexopoulos","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/00365590801943241","article-title":"C5b-9 glomerular deposition and tubular \u03b13\u03b21-integrin expression are implicated in the development of chronic lesions and predict renal function outcome in immunoglobulin A nephropathy","volume":"42","author":"Stangou","year":"2008","journal-title":"Scand J Urol Nephrol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12014-017-9165-x","article-title":"Glomerular abundance of complement proteins characterized by proteomic analysis of laser-captured microdissected glomeruli associates with progressive disease in IgA nephropathy","volume":"14","author":"Paunas","year":"2017","journal-title":"Clin Proteomics"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000384","article-title":"Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: A randomized controlled trial","volume":"19","author":"Barratt","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2004.11.016","article-title":"Functional analysis of the classical, alternative, and MBL pathways of the complement system: Standardization and validation of a simple ELISA","volume":"296","author":"Seelen","year":"2005","journal-title":"J Immunol Methods"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfv076","article-title":"Use of eculizumab in crescentic IgA nephropathy: Proof of principle and conundrum","volume":"8","author":"Ring","year":"2015","journal-title":"Clin Kidney J"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-014-2863-y","article-title":"Eculizumab treatment for rescue of renal function in IgA nephropathy","volume":"29","author":"Rosenblad","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy: A phase 2 randomized double-blind placebo-controlled trial","author":"Lafayette","year":"9900","journal-title":"J Am Soc Nephrol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab294","article-title":"C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study","volume":"15","author":"Bruchfeld","year":"2022","journal-title":"Clin Kidney J"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.08.003","article-title":"Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy","volume":"5","author":"Lafayette","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq559","article-title":"Spontaneous remission of nephrotic syndrome in patients with IgA nephropathy","volume":"26","author":"Han","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B78","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2017060713","article-title":"Effects of two immunosuppressive treatment protocols for IgA nephropathy","volume":"29","author":"Rauen","year":"2018","journal-title":"J Am Soc Nephrol"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1545329\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:28:41Z","timestamp":1738646921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1545329\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":78,"alternative-id":["10.3389\/fneph.2025.1545329"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2025.1545329","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"article-number":"1545329"}}